242 related articles for article (PubMed ID: 23158070)
1. [The negative enrichment by immunomagnetic beads for tumor cells from malignant pleural effusions].
Yang JJ; Xu XX; Min LF; Lin P; Qian GS
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Sep; 35(9):673-8. PubMed ID: 23158070
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of two fluorescence in situ hybridization (FISH) probes for diagnosing malignant pleural effusions.
Rosolen DC; Kulikowski LD; Bottura G; Nascimento AM; Acencio M; Teixeira L; Vargas FS; Sales RK; Antonangelo L
Lung Cancer; 2013 Jun; 80(3):284-8. PubMed ID: 23453645
[TBL] [Abstract][Full Text] [Related]
3. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
4. Detection of hyperdiploid malignant cells in pleural effusions with chromosome-specific probes and fluorescence in situ hybridization.
Johnson TM; Kuffel DG; Dewald GW
Mayo Clin Proc; 1996 Jul; 71(7):643-8. PubMed ID: 8656705
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of tumor markers in lung adenocarcinoma-associated cytologically negative pleural effusions.
Hsieh TC; Huang WW; Lai CL; Tsao SM; Su CC
Cancer Cytopathol; 2013 Sep; 121(9):483-8. PubMed ID: 23408492
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic value of DNA, RNA and proliferating cell nuclear antigen examination in malignant pleural effusions by flow cytometry].
Wang LX; Chen WX; Wu J; Chen SX; Huang XY; Chen YF
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Dec; 29(12):804-7. PubMed ID: 17327081
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence in situ hybridization as adjunct to cytology improves the diagnosis and directs estimation of prognosis of malignant pleural effusions.
Han J; Cao S; Zhang K; Zhao G; Xin Y; Dong Q; Yan Y; Cui J
J Cardiothorac Surg; 2012 Nov; 7():121. PubMed ID: 23148562
[TBL] [Abstract][Full Text] [Related]
8. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.
Matsumoto S; Nabeshima K; Kamei T; Hiroshima K; Kawahara K; Hata S; Marukawa K; Matsuno Y; Taguchi K; Tsujimura T
Cancer Cytopathol; 2013 Aug; 121(8):415-22. PubMed ID: 23450849
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
Hyun TS; Barnes M; Tabatabai ZL
Acta Cytol; 2012; 56(5):527-32. PubMed ID: 23075894
[TBL] [Abstract][Full Text] [Related]
10. Limitations of detection of malignancy in pleural effusions using ELISA-based TRAP assay: comparison with cytological examination.
Lee WY
Cytopathology; 2005 Oct; 16(5):227-32. PubMed ID: 16181308
[TBL] [Abstract][Full Text] [Related]
11. hTERT gene amplification and clinical significance in pleural effusions of patients with lung cancer.
Cha N; Li XY; Zhao YJ; Wang EH; Wu GP
Clin Lung Cancer; 2012 Nov; 13(6):494-9. PubMed ID: 22464057
[TBL] [Abstract][Full Text] [Related]
12. Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions.
Flores-Staino C; Darai-Ramqvist E; Dobra K; Hjerpe A
Lung Cancer; 2010 Apr; 68(1):39-43. PubMed ID: 19523712
[TBL] [Abstract][Full Text] [Related]
13. Glucose transporter 1 protein detected by enzyme-linked immunosorbent assay and immunocytochemistry: a useful diagnostic tool for malignant pleural effusions.
Liao ND; Chiang TA; Lee WY
Cancer Cytopathol; 2013 Dec; 121(12):695-702. PubMed ID: 23861325
[TBL] [Abstract][Full Text] [Related]
14. Combination of cytology, fluorescence in situ hybridization for aneuploidy, and reverse-transcriptase polymerase chain reaction for human mammaglobin/mammaglobin B expression improves diagnosis of malignant effusions.
Fiegl M; Haun M; Massoner A; Krugmann J; Müller-Holzner E; Hack R; Hilbe W; Marth C; Duba HC; Gastl G; Grünewald K
J Clin Oncol; 2004 Feb; 22(3):474-83. PubMed ID: 14752070
[TBL] [Abstract][Full Text] [Related]
15. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
16. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology.
Savic S; Franco N; Grilli B; Barascud Ade V; Herzog M; Bode B; Loosli H; Spieler P; Schönegg R; Zlobec I; Clark DP; Herman JG; Bubendorf L
Chest; 2010 Jul; 138(1):137-44. PubMed ID: 20139227
[TBL] [Abstract][Full Text] [Related]
17. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R
Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
[TBL] [Abstract][Full Text] [Related]
18. Can we improve the cytologic examination of malignant pleural effusions using molecular analysis?
Brock MV; Hooker CM; Yung R; Guo M; Han Y; Ames SE; Chang D; Yang SC; Mason D; Sussman M; Baylin SB; Herman JG
Ann Thorac Surg; 2005 Oct; 80(4):1241-7. PubMed ID: 16181847
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions.
Gaspar MJ; De Miguel J; García Díaz JD; Díez M
Anticancer Res; 2008; 28(5B):2947-52. PubMed ID: 19031938
[TBL] [Abstract][Full Text] [Related]
20. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
Onofre FB; Onofre AS; Pomjanski N; Buckstegge B; Grote HJ; Böcking A
Cancer; 2008 Jun; 114(3):204-15. PubMed ID: 18306350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
